| Market Cap | $328.55M-6.8% |
| Revenue (ttm) | n/a |
| Net Income | -$156.03M |
| EPS | -$1.67 |
| Shares Out | 104.63M |
| PE Ratio | n/a |
| Forward PE | -3.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,707,224 |
| Open | $3.15 |
| Previous Close | $3.22 |
| Day's Range | $2.96 - $3.22 |
| 52-Week Range | $1.92 - $6.42 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | $14.20(+352.23%) |
| Earnings Date | Nov 16, 2026 |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc. Stock Analysis — InsiderScore
Larimar Therapeutics, Inc. scored higher than 56% of companies evaluated by InsiderBuying, and ranked 33rd out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Larimar Therapeutics, Inc. bought $392.1K of stock across 8 purchases in the last 90 days, the largest of them $187.1K.
The average purchase added about 46% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LRMR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LRMR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LRMR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LRMR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LRMR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LRMR from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from LRMR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst maintained positive rating despite price target cut; regulatory progress on lead program offsets mixed near-term signals.
Recent Insider Activity
Insider Score Trend Over Time
-1.3 since Nov 13Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.23% |
| IBRN | iShares Neuroscience and Healthcare ETF | 0.11% |
| OMFS | Invesco Russell 2000 Dynamic Multifactor ETF | 0.09% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.07% |
| FSCC | Federated Hermes MDT Small Cap Core ETF | 0.06% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.05% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.04% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| IBB | iShares Biotechnology ETF | 0.01% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
